GlassScriptPhysician profile
Gerald J Levinson
NPI 1295749471
$3,580.84
in general payments reported to CMS, 2019-2025
32 companies · $21.89 in 2025
The $21.89 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $168 · 2021: $256 · 2022: $1,110 · 2023: $757 · 2025: $21.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $808.92 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $702.15 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $341.41 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $230.57 | 2019-2023 | Breztri |
| Novartis Pharmaceuticals Corporation | $177.14 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.82 | 2022-2023 | Jardiance |
| Abbvie INC. | $131.83 | 2019-2023 | |
| Pfizer INC. | $129.55 | 2019 | |
| Astellas Pharma US INC | $126.34 | 2019-2023 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $126.25 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $124.99 | 2019-2022 | |
| Shield Therapeutics INC | $56.30 | 2022-2023 | Accrufer |
| Exact Sciences Corporation | $42.70 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $37.46 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.93 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36.80 | 2019 | |
| Lilly USA, LLC | $31.43 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $29.97 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $29.30 | 2023 | |
| Alexion Pharmaceuticals, INC. | $28.94 | 2019 | |
| Daiichi Sankyo INC. | $28.29 | 2023 | Injectafer |
| Janssen Biotech, INC. | $25.96 | 2019-2020 | |
| Abbott Laboratories | $21.89 | 2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $18.50 | 2023 | Unithroid |
| Travere Therapeutics, INC. | $17.87 | 2022 | |
| Baxter Healthcare | $15.32 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $15.13 | 2023 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.62 | 2023 | Xifaxan |
| Dexcom, INC. | $14.45 | 2023 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $13.33 | 2023 | Contrave |
| Amarin Pharma, INC. | $12.93 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.